

F. Lichten

November 8, 1974

Elliott Richelson, M.D.
Johns Hopkins University School of Medicine
Baltimore, Maryland

Dear Dr. Richelson,

For a number of years I have been studying the CNS effects of standard and novel psychoactive compounds. In answer to your inquiry, I have examined the compounds under study and find that none would earn the classification of 'antipsychotic'-- indeed, we have not assessed a new antipsychotic since our studies of butaperazine, thiothixene, and trifluoperidol-- and none of these would fit the sense of a 'new neuroleptic'. I regret this fact, and thank you for your inquiry.

My best regards to Professor Elkes.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

mf/